Astrazeneca will invest $2 billion in its facility in Maryland, USA

AASTOCKS
2025.11.21 21:37

Astrazeneca (AZN.US) announced on Friday that it will invest $2 billion in its facilities located in Maryland, USA, to build new production capacity aimed at accelerating the production of drugs for cancer, rare diseases, and chronic conditions.

The investment includes the expansion of its flagship biopharmaceutical manufacturing facility in Frederick, as well as the construction of a new facility in Gaithersburg for the research and clinical trial supply of innovative molecular drugs. The company stated that by 2029, this investment will support 2,600 jobs in the state, including construction positions and 300 high-skilled jobs.

CEO Pascal Soirot stated that this investment enhances the resilience of the U.S. drug supply chain and accelerates access to transformative therapies for patients globally and across the United States

Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.